Nurix Therapeutics (NRIX) Competitors $11.32 -0.77 (-6.36%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, VKTX, and PTGXShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Its Competitors Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics Avidity Biosciences ACADIA Pharmaceuticals Scholar Rock Viking Therapeutics Protagonist Therapeutics Ultragenyx Pharmaceutical (NASDAQ:RARE) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings. Does the media refer more to RARE or NRIX? In the previous week, Ultragenyx Pharmaceutical had 36 more articles in the media than Nurix Therapeutics. MarketBeat recorded 53 mentions for Ultragenyx Pharmaceutical and 17 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.30 beat Ultragenyx Pharmaceutical's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 7 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral Nurix Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of RARE or NRIX? 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is RARE or NRIX more profitable? Ultragenyx Pharmaceutical has a net margin of -93.04% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-93.04% -186.49% -36.81% Nurix Therapeutics -234.57%-45.26%-34.71% Which has more volatility & risk, RARE or NRIX? Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Which has stronger earnings & valuation, RARE or NRIX? Nurix Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M4.52-$569.18M-$5.88-4.55Nurix Therapeutics$54.55M15.87-$193.57M-$2.61-4.34 Do analysts recommend RARE or NRIX? Ultragenyx Pharmaceutical presently has a consensus price target of $83.64, suggesting a potential upside of 212.52%. Nurix Therapeutics has a consensus price target of $29.31, suggesting a potential upside of 158.92%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.82 SummaryNurix Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$863.35M$2.92B$5.50B$9.40BDividend YieldN/A2.45%3.80%4.05%P/E Ratio-4.3320.1228.0819.84Price / Sales15.87307.21433.99100.72Price / CashN/A43.1635.8457.94Price / Book1.947.718.145.64Net Income-$193.57M-$55.21M$3.24B$257.97M7 Day Performance-9.00%3.03%1.26%2.12%1 Month Performance-2.57%12.34%7.68%11.21%1 Year Performance-46.47%4.92%30.07%18.36% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.4861 of 5 stars$11.32-6.4%$29.31+158.9%-44.5%$863.35M$54.55M-4.33300Analyst ForecastAnalyst RevisionRAREUltragenyx Pharmaceutical4.3876 of 5 stars$39.61-0.8%$87.00+119.6%-37.5%$3.77B$560.23M0.001,294Trending NewsAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.73B$134.35M0.00600Lockup ExpirationMRUSMerus1.9483 of 5 stars$52.58-2.3%$84.64+61.0%+8.6%$3.73B$36.13M0.0037ACLXArcellx2.5333 of 5 stars$65.55-2.4%$111.23+69.7%+8.3%$3.70B$107.94M0.0080Positive NewsSWTXSpringWorks Therapeutics1.3666 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoverageRNAAvidity Biosciences2.1939 of 5 stars$28.80-1.3%$65.59+127.7%-24.6%$3.52B$10.90M0.00190ACADACADIA Pharmaceuticals3.9885 of 5 stars$20.88-0.3%$27.88+33.5%+22.9%$3.51B$957.80M15.24510SRRKScholar Rock3.1313 of 5 stars$35.48-1.4%$42.67+20.3%+378.9%$3.42B$33.19M0.00140Analyst ForecastVKTXViking Therapeutics4.6464 of 5 stars$27.51-2.4%$87.15+216.8%-35.7%$3.17BN/A0.0020Positive NewsUpcoming EarningsPTGXProtagonist Therapeutics1.4498 of 5 stars$49.87-2.3%$66.10+32.5%+57.1%$3.16B$434.43M68.07120Positive News Related Companies and Tools Related Companies RARE Alternatives AAPG Alternatives MRUS Alternatives ACLX Alternatives SWTX Alternatives RNA Alternatives ACAD Alternatives SRRK Alternatives VKTX Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy...Brownstone Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | Sponsored“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMiss This Window And You Miss EverythingThere’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the ph...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
